BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17304159)

  • 1. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
    Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
    Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
    Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K
    Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics.
    Mamiya K; Hadama A; Yukawa E; Ieiri I; Otsubo K; Ninomiya H; Tashiro N; Higuchi S
    Eur J Clin Pharmacol; 2000; 55(11-12):821-5. PubMed ID: 10805060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
    Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH
    Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
    Lee SY; Lee ST; Kim JW
    J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
    Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
    Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach.
    Yukawa E; Mamiya K
    J Clin Pharm Ther; 2006 Jun; 31(3):275-82. PubMed ID: 16789993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
    Liao K; Liu Y; Ai CZ; Yu X; Li W
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.
    Saruwatari J; Ogusu N; Shimomasuda M; Nakashima H; Seo T; Tanikawa K; Tsuda Y; Nishimura M; Nagata R; Yasui-Furukori N; Kaneko S; Ishitsu T; Nakagawa K
    Ther Drug Monit; 2014 Jun; 36(3):302-9. PubMed ID: 24345815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
    Allabi AC; Gala JL; Horsmans Y
    Pharmacogenet Genomics; 2005 Nov; 15(11):779-86. PubMed ID: 16220110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.
    Jiao Z; Shi XJ; Zhao ZG; Zhong MK
    J Clin Pharm Ther; 2004 Jun; 29(3):247-56. PubMed ID: 15153086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
    Song C; Li X; Mao P; Song W; Liu L; Zhang Y
    Eur J Hosp Pharm; 2022 Jul; 29(4):198-201. PubMed ID: 32868386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures.
    Lee SM; Chung JY; Lee YM; Park MS; Namgung R; Park KI; Lee C
    Arch Dis Child; 2012 Jun; 97(6):569-72. PubMed ID: 22331680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
    Lin CJ; Yen MF; Hu OY; Lin MS; Hsiong CH; Hung CC; Liou HH
    Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling.
    Jiang D; Bai X; Zhang Q; Lu W; Wang Y; Li L; Müller M
    Eur J Clin Pharmacol; 2009 Dec; 65(12):1187-93. PubMed ID: 19756559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
    Yin OQ; Tomlinson B; Chow MS
    Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
    Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
    Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
    Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
    Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.